r th I t L 1 The Proper th i Commercial business is performing well "We are all-in on immunology, across therapeutic areas." We are all-in on Immunology, across therapeutic areas Unprecedented pipeline of blockbuster opportunities Amlitelimab shows significant improvements in signs In addition to the healthy immunology pipeline, we should see business development transactions that should complement the product portfolio and pipeline. Management seems more focused on bolt-on deals in the range EUR2 billion t ...

Investment thesis Wall Street's indifference to France's largest pharmaceutical company is reflected in its share price continuing to move sideways despite its rich pipeline of approved and experimental medicines, rising dividend payouts, and relatively low debt. In my estimation, in addition to the product candidates, some of which could become "gold standards" in the treatment of autoimmune diseases, other key contributors to strengthening Sanofi's balance sheet are innovative drugs such as Dupixent, Nexv ...

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) followed by Sarclisa-Rd reduced the risk of recurrence or death by 40% versus VRd followed by Rd in the investigational use for transplant-ineligible newly diagnosed multiple myeloma patients Key primary endpoint of progression-free surv ...

Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi's global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries. Now in its 10th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to secure that employees benefit from the company growth and success. Paul Hudson Chief Executive Officer of Sanofi "This plan underscores our ongoing commitment to unite the people of Sanofi behind our l ...

Sanofi completes acquisition of Inhibrx, Inc. Paris, May 30, 2024. Sanofi announced today the completion of its acquisition of Inhibrx, Inc. ("Inhibrx"). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi's rare disease pipeline, underscoring the company's commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AAT ...

BARCELONA, Spain, May 28, 2024 /PRNewswire/ -- Sanofi is all in on AI and wants to become the first biopharma company powered by AI at scale. The company is using AI to chase the miracles of science by accelerating drug discovery, enhancing clinical trial design and improving the manufacturing and supply of medicines and vaccines to get them to patients in need faster. Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation. The company is ...

The sBLA seeks approval for Sarclisa in combination with Velcade (bortezomib), Bristol-Myers' (BMY) Revlimid (lenalidomide) and dexamethasone (VRd) for the treatment of patients with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible. With the FDA granting a priority review to the sBLA, a decision from the regulatory body is expected on Sep 27, 2024. A similar regulatory application is also currently under review in the European Union. The sBLA and the application in the EU were based on ...

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma Paris, May 27, 2024. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). If approved, Sarclisa ...

Sanofi (SNY) announced that it has entered into a first-in-class artificial intelligence (AI) collaboration with Formation Bio and OpenAI to build AI-powered software to expedite the development of drugs. Formation Bio is a tech-driven, AI-native pharma company focused on bringing new treatments to patients with more efficient drug development, while OpenAI is an AI research and deployment company. Per the press release, the companies are collaborating to bring together data, software and tuned models aimed ...

Core Insights - Sanofi, Formation Bio, and OpenAI are collaborating to create AI-powered software aimed at accelerating drug development and improving the efficiency of bringing new medicines to patients [1][2][3] - This partnership marks a pioneering collaboration in the pharmaceutical and life sciences sectors, focusing on custom solutions throughout the drug development lifecycle [1][4] Company Summaries Sanofi - Sanofi aims to become the first biopharma company powered by AI at scale, leveraging proprietary data to develop advanced AI models [2][3] - The CEO of Sanofi emphasized that this collaboration is a significant step towards transforming drug development and addressing the needs of patients awaiting innovative treatments [3][5] Formation Bio - Formation Bio is characterized as a tech-driven and AI-native pharmaceutical company, focused on enhancing drug development efficiency [6] - The company provides engineering resources and operates at the intersection of pharma and AI, aiming to accelerate all aspects of drug development and clinical trials [4][6] OpenAI - OpenAI contributes its leading AI capabilities, including model fine-tuning and deep AI expertise, to support the collaboration [3][4] - The COO of OpenAI highlighted the immense potential of AI to expedite drug development and improve patient outcomes [4][5]